Based on in vivo and in vitro studies, we revealed that XBP1s enhanced the expression of E2F1 target genes by transcriptional activation of SND1, thereby exerting a pro‐survival effect in patients with HR+/HER2− breast cancer receiving the combined therapy. The gene discussed is E2F1; the disease is breast carcinoma.